205 related articles for article (PubMed ID: 21887475)
21. Deregulation of LIMD1-VHL-HIF-1α-VEGF pathway is associated with different stages of cervical cancer.
Chakraborty C; Mitra S; Roychowdhury A; Samadder S; Dutta S; Roy A; Das P; Mandal RK; Sharp TV; Roychoudhury S; Panda CK
Biochem J; 2018 May; 475(10):1793-1806. PubMed ID: 29654110
[TBL] [Abstract][Full Text] [Related]
22. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
Aprelikova O; Chandramouli GV; Wood M; Vasselli JR; Riss J; Maranchie JK; Linehan WM; Barrett JC
J Cell Biochem; 2004 Jun; 92(3):491-501. PubMed ID: 15156561
[TBL] [Abstract][Full Text] [Related]
23. Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion.
Demidenko ZN; Rapisarda A; Garayoa M; Giannakakou P; Melillo G; Blagosklonny MV
Oncogene; 2005 Jul; 24(30):4829-38. PubMed ID: 15897903
[TBL] [Abstract][Full Text] [Related]
24. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein.
Yu F; White SB; Zhao Q; Lee FS
Cancer Res; 2001 May; 61(10):4136-42. PubMed ID: 11358837
[TBL] [Abstract][Full Text] [Related]
25. No evidence for DNA methylation of von Hippel-Lindau ubiquitin ligase complex genes in breast cancer.
Huang KT; Dobrovic A; Fox SB
Breast Cancer Res Treat; 2010 Dec; 124(3):853-6. PubMed ID: 20680678
[TBL] [Abstract][Full Text] [Related]
26. [HIF-1alpha, HIF-2alpha and VHL mRNA expression in different cell lines during hypoxia].
Bobarykina AIu; Minchenko DO; Opentanova IL; Kovtun OO; Komisarenko SV; Esumi H; Minchenko OH
Ukr Biokhim Zh (1999); 2006; 78(2):62-72. PubMed ID: 17100286
[TBL] [Abstract][Full Text] [Related]
27. A yeast three-hybrid system that reconstitutes mammalian hypoxia inducible factor regulatory machinery.
Alcaide-German ML; Vara-Vega A; Garcia-Fernandez LF; Landazuri MO; del Peso L
BMC Cell Biol; 2008 Apr; 9():18. PubMed ID: 18402654
[TBL] [Abstract][Full Text] [Related]
28. The Caenorhabditis elegans rhy-1 gene inhibits HIF-1 hypoxia-inducible factor activity in a negative feedback loop that does not include vhl-1.
Shen C; Shao Z; Powell-Coffman JA
Genetics; 2006 Nov; 174(3):1205-14. PubMed ID: 16980385
[TBL] [Abstract][Full Text] [Related]
29. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
30. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
Nyhan MJ; O'Sullivan GC; McKenna SL
Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
[TBL] [Abstract][Full Text] [Related]
31. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
32. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis.
Maxwell PH; Pugh CW; Ratcliffe PJ
Adv Exp Med Biol; 2001; 502():365-76. PubMed ID: 11950150
[TBL] [Abstract][Full Text] [Related]
33. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564.
Harada H; Kizaka-Kondoh S; Hiraoka M
FEBS Lett; 2006 Oct; 580(24):5718-22. PubMed ID: 17010341
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
[TBL] [Abstract][Full Text] [Related]
37. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia inducible factor-1α-mediated activation of survivin in cervical cancer cells.
Bai H; Ge S; Lu J; Qian G; Xu R
J Obstet Gynaecol Res; 2013 Feb; 39(2):555-63. PubMed ID: 22925504
[TBL] [Abstract][Full Text] [Related]
39. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation.
Yu F; White SB; Zhao Q; Lee FS
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9630-5. PubMed ID: 11504942
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Périgny M; Hammel P; Corcos O; Larochelle O; Giraud S; Richard S; Sauvanet A; Belghiti J; Ruszniewski P; Bedossa P; Couvelard A
Am J Surg Pathol; 2009 May; 33(5):739-48. PubMed ID: 19238077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
